1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2024

EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2024

Summary

Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths around the axons of the brain and spinal cord are damaged, leading to demyelination and a wide range of signs and symptoms. The course of MS seems to be unpredictable as some people diagnosed with the condition appear to be normal and healthy for a few years after diagnosis, while others may be debilitated very quickly after diagnosis. People with MS experience a host of symptoms, which may vary with the course of the disease. The estimated prevalence and incidence of MS vary greatly between countries, within countries, and by age and sex.

In 2014, there were a total of 909,398 diagnosed prevalent cases of MS in the 10MM, and GlobalData epidemiologists forecast that by 2024, the number of diagnosed prevalent cases of MS will grow to 942,567 cases. In 2014, there were a total of 60,535 diagnosed incident cases of MS in the 10MM, and GlobalData epidemiologists forecast the number of diagnosed incident cases of MS to grow to 62,635 cases in the 10MM in 2024.

GlobalData epidemiologists forecast the diagnosed prevalent and diagnosed incident cases of MS in the 10MM from 2014-2024 using country-specific studies published in peer-reviewed journals that provided the age- and sex-specific diagnosed prevalence and diagnosed incidence of MS in the respective markets. The epidemiologists made sure that all the selected nationally-representative studies in the respective countries assessed the prevalence and incidence using the same study definition, thereby ensuring that the results forecast for each country are comparable. The forecast methodology was consistent across all the 10MM to allow for a meaningful comparison among them.

Scope

- The Multiple Sclerosis (MS) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for MS in the ten major markets (10MM) (US, France, Germany, Italy, Spain, UK, Japan, Canada, China, and India). It includes a 10-year epidemiological forecast of the diagnosed prevalent and diagnosed incident cases of MS segmented by sex and age in these markets. This report also includes a discussion of three types of MS; relapse remitting (RRMS), primary progressive (PPMS), and secondary progressive (SPMS).
- The MS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global MS market.
- Quantify patient populations in the global MS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for MS therapeutics in each of the markets covered.

Table Of Contents

EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2024
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 7
2.3 Upcoming Related Reports 7
3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors and Comorbidities 9
3.2.1 Family members of MS patients have a 1-5% risk of developing MS 10
3.2.2 Women are twice as likely to develop MS, but men have a worse prognosis 11
3.2.3 Caucasians have a higher risk of MS than any other race/ethnicity 11
3.2.4 Protective effect of vitamin D on MS may relate to latitude and month of birth 11
3.2.5 Timing of environmental exposures affects MS risk 12
3.2.6 Exposure to smoking may increase MS risk and worsen prognosis 12
3.2.7 Autoimmune diseases are comorbidities of MS 13
3.2.8 Mental comorbidities are found in up to 60% of MS patients and may affect relapse rates 13
3.3 Global Trends 14
3.3.1 North America 14
3.3.2 Europe 16
3.3.3 Asia 16
3.4 Forecast Methodology 17
3.4.1 Sources Used 19
3.4.2 Sources Not Used 25
3.4.3 Forecast Assumptions and Methods 25
3.5 Epidemiological Forecast for MS (2014-2024) 32
3.5.1 Diagnosed Prevalent Cases of MS 32
3.5.2 Age-Specific Diagnosed Prevalent Cases of MS 34
3.5.3 Sex-Specific Diagnosed Prevalent Cases of MS 36
3.5.4 Diagnosed Incident Cases of MS 38
3.5.5 Age-Specific Diagnosed Incident Cases of MS 40
3.5.6 Sex-Specific Diagnosed Incident Cases of MS 42
3.5.7 MS Subtypes 43
3.6 Discussion 44
3.6.1 Epidemiological Forecast Insight 44
3.6.2 Limitations of the Analysis 45
3.6.3 Strengths of the Analysis 45
4 Appendix 46
4.1 Bibliography 46
4.2 About the Authors 53
4.2.1 Epidemiologists 53
4.2.2 Reviewers 54
4.2.3 Global Director of Therapy Analysis and Epidemiology 54
4.2.4 Global Head of Healthcare 55
4.3 About GlobalData 56
4.4 About EpiCast 56
4.5 Disclaimer 57

1.1 List of Tables
Table 1: Risk Factors and Comorbidites for MS 10
Table 2: Sources of MS Diagnosed Prevalence and Diagnosed Incidence Data Used in the Epidemiology Forecast 18
Table 3: 10MM, Diagnosed Prevalent Cases of MS, Ages ?20 Years, Men and Women, N, Select Years, 2014-2024 33
Table 4: 10MM, Diagnosed Prevalent Cases of MS, by Age, Men and Women, N (Row %), 2014 35
Table 5: 10MM, Diagnosed Prevalent Cases of MS, Ages ?20 Years, by Sex, N (Row %), 2014 37
Table 6: 10MM, Diagnosed Incident Cases of MS, Ages ?20 Years, Men and Women, N, Select Years, 2014-2024 39
Table 7: 10MM, Diagnosed Incident Cases of MS, by Age, Men and Women, N (Row %), 2014 41
Table 8: 10MM, Diagnosed Incident Cases of MS, by Sex, N (Row %), 2014 42

1.2 List of Figures
Figure 1: 10MM, Diagnosed Prevalent Cases of MS, Ages ?20 Years, Men and Women, N, Select Years, 2014-2024 34
Figure 2: 10MM, Diagnosed Prevalent Cases of MS, by Age, Men and Women, N, 2014 36
Figure 3: 10MM, Diagnosed Prevalent Cases of MS, Ages ?20 Years, by Sex, N, 2014 38
Figure 4: 10MM, Diagnosed Incident Cases of MS, Ages ?20 Years, Men and Women, N, Select Years, 2014-2024 40
Figure 5: 10MM, Diagnosed Incident Cases of MS, by Age, Men and Women, N, 2014 41
Figure 6: 10MM, Diagnosed Incident Cases of MS, by Sex, N, 2014 43
Figure 7: 10MM, MS Subtype Distributions, %*, 2014 44

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Epilepsy

Epilepsy

  • $ 5 000
  • Industry report
  • June 2016
  • by Datamonitor Healthcare

Refractory patients, niche indication expansions, and geographical reach offer room for growth in an otherwise crowded epilepsy market. This report addresses the following questions: - Why do leading antiepileptic ...

Epilepsy Drugs Market Analysis By Treatment (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics), And Segment Forecasts To 2024

Epilepsy Drugs Market Analysis By Treatment (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics), And Segment Forecasts To 2024

  • $ 4 700
  • Industry report
  • July 2016
  • by Grand View Research

The global epilepsy drugs market is expected to reach over USD 5,474.14 million by 2024, according to a new report by Grand View Research, Inc. The rising government funding for the development of new ...

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) - Pipeline Review, H1 2016

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) - Pipeline Review, H1 2016

  • $ 3 500
  • Industry report
  • June 2016
  • by Global Markets Direct

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.